Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NUP98
REST API REST API
Homo sapiens
NUP98 is differentially expressed in 349 experiments: 165 organism parts: testis, bone marrow, ... (163 more);, 255 disease states: normal, control, ... (253 more);, 97 cell types 459 cell lines 49 compound treatments and 77 other conditions.
Synonyms NUP96
Orthologs NUP98 (Bos taurus)   ENSCING00000000557 (Ciona intestinalis)   ENSCING00000015542 (Ciona intestinalis)   ENSCING00000015547 (Ciona intestinalis)   Nup98 (Rattus norvegicus)   NUP98 (Gallus gallus)   Nup98 (Drosophila melanogaster)   nup98 (Danio rerio)   Nup98 (Mus musculus)   NUP145 (Saccharomyces cerevisiae)   nup98 (Xenopus laevis)   NUP98 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transporter activity, cytosol, transport, M phase of mitotic cell cycle, protein binding, kinetochore, mRNA transport, membrane, mitotic cell cycle, mitotic prometaphase, structural constituent of nuclear pore, peptide binding, nucleus, carbohydrate metabolic process, nuclear envelope, nuclear pore, transmembrane transport, nucleoplasm, nucleocytoplasmic transport, protein import into nucleus, docking, DNA replication, protein transport, nuclear membrane, viral reproduction, glucose transport, Nup107-160 complex, interspecies interaction between organisms, nuclear pore organization, regulation of glucose transport, hexose transport
InterPro Term Peptidase_S59, Nup96
UniProt Accession P52948, Q9HDC8, E9PNN0
Search EB-eye ENSG00000110713
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-2549, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
MDA-MB-231
3
E-TABM-420, E-MTAB-62, E-GEOD-5823
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
453 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-GEOD-3920, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
monocyte at intermediate differentiation stage
1
E-GEOD-5099
LCC
1
E-GEOD-19188
activated B-cell
1
E-MEXP-2360
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (71 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-96
glioblastoma
1
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-37, E-MTAB-62
astrocytoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
249 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (30 experiments)

Factor Value U/D Experiments
none
4
7
E-TABM-782, E-GEOD-5824, E-MEXP-1601, E-GEOD-20719, E-MEXP-1958, ... (11 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
control
1
2
E-GEOD-3284, E-GEOD-4006, E-GEOD-5339
filtered air
1
E-TABM-127
mercaptopurine, methotrexate
1
E-GEOD-412
camptothecin
1
E-GEOD-1417
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-22513, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-TABM-1029, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (18 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-GEOD-697, E-MEXP-1274, E-GEOD-12108, E-GEOD-9723, E-GEOD-6927, ... (6 experiments)

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (11 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.262 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM